A federal grand jury indicted Hoau-Yan Wang, for falsifying data to secure grants for Alzheimer's research, impacting Cassava Sciences' drug simufilam in advanced clinical trials.
Controversy arose as some scientists discredited simufilam's efficacy, leading to accusations of manipulated results by Cassava Sciences and Dr. Wang, with retracted publications and stock price plummeting.
Collection
[
|
...
]